Skip to main content
Clinical Trials/NL-OMON52225
NL-OMON52225
Recruiting
Not Applicable

The use of single cell genomics to identify chromosomal alterations driving resistance to palbociclib in metastatic breast cancer patients - PALETTE

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Erasmus MC, Universitair Medisch Centrum Rotterdam
Enrollment
48
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Adult women (\>\= 18 years of age) with proven diagnosis of adenocarcinoma of
  • the breast with locoregional recurrent or metastatic disease not amenable to
  • resection or radiation therapy with curative intent.
  • 2\. Documentation of histologically or cytologically confirmed diagnosis of
  • estrogen receptor (ER) expression \>10% and/or progesterone receptor (PR)
  • expression \>10% breast cancer based on local laboratory results. Tumor must be
  • HER2\-negative as defined by ASCO\-CAP guidelines (ref).
  • 3\. Patients starting the combination endocrine therapy \+ palbociclib as first
  • or a subsequent treatment line for metastatic disease.
  • 4\. Patients must have evaluable disease as per RECIST v.1\.1\.

Exclusion Criteria

  • 1\. Pre\-existing lymphedema in one or both arms, diagnosed by the treating
  • medical oncologist
  • 2\. Patients with known hypersensitivity to the anticoagulant used for apheresis
  • 3\. Patients with inadequate cardiac function or severe cardiovascular
  • comorbidity:
  • \- Heart failure NYHA class III/IV
  • 4\. Hemoglobin level \< 6\.0 mmol/L
  • 5\. Coagulation disorders as defined by one of the following
  • \- Coagulation disorder in medical history
  • \- Platelet count \< 40 x 109/L;

Outcomes

Primary Outcomes

Not specified

Similar Trials